Marshall Wace’s Arcturus Therapeutics ARCT Stock Holding History

Marshall Wace’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$519K	Buy	+77,269	New	+$609K	﹤0.01%	2503
2024 Q3	–	Sell	-45,219	Closed	-$1.1M	–	2476
2024 Q2	$1.1M	Sell	45,219 -39,048	-46%	-$1.18M	﹤0.01%	1643
2024 Q1	$2.85M	Buy	+84,267	New	+$2.99M	﹤0.01%	1219
2023 Q4	–	Sell	-90,010	Closed	-$2.3M	–	2155
2023 Q3	$2.3M	Buy	90,010 +5,639	+7%	+$174K	﹤0.01%	1165
2023 Q2	$2.42M	Buy	+84,371	New	+$2.3M	﹤0.01%	1312
2021 Q4	–	Sell	-11,062	Closed	-$528K	–	3836
2021 Q3	$528K	Buy	+11,062	New	+$496K	﹤0.01%	2357
2020 Q4	–	Sell	-7,689	Closed	-$330K	–	1857
2020 Q3	$330K	Buy	+7,689	New	+$382K	﹤0.01%	1343
2015 Q2	–	Sell	-11,169	Closed	-$440K	–	891
2015 Q1	$440K	Buy	+11,169	New	+$491K	0.01%	688

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace's ARCT Position: Q2 2026 in Review

Marshall Wace opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 77,269 shares worth $519K. The stake represents ﹤0.01% of the portfolio and ranks #2503 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ARCT as recently as Q2 2024.

Marshall Wace first reported a position in ARCT in Q1 2015 and has held it in 8 quarters since. The position peaked at $2.85M in Q1 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Marshall Wace held 77,269 shares of Arcturus Therapeutics worth $519K as of Q2 2026.
Arcturus Therapeutics was a new Marshall Wace position in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2503 holding.
Marshall Wace first reported a position in Arcturus Therapeutics in Q1 2015 and has held it in 8 quarters since.
Marshall Wace's Arcturus Therapeutics position peaked at $2.85M in Q1 2024.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.